Restoring Inflammatory Mediator Balance after Sofosbuvir-Induced Viral Clearance in Patients with Chronic Hepatitis C
Table 1
Baseline demographic and clinical characteristics of chronic hepatitis C patients.
Characteristics
Age in years, mean ± SD (min–max)
59.4 ± 8.95 (23.0–73.0)
Gender, (%)
Female/male
61 (69.32)/27 (30.68)
HCV genotype, (%)
1
71 (80.68)
3
16 (18.18)
4
1 (1.14)
HCV viral load (IU/mL), mean (±SD)
17.7 × 105 (±34.7 × 105)
Liver disease status, (%)
F0–F3
17.0 (19.32)
F4
Child A
58.0 (65.91)
Child B or C
13.0 (14.77)
ALT (U/L), median (IQR)
99.0 (64.5–134.8)
AST (U/L), median (IQR)
73.5 (46.2–117.0)
Albumin (g/dL), median (IQR)
3.45 (3.1–3.8)
PT (seconds), median (IQR)
13.0 (12.2–14.3)
INR, median (IQR)
1.18 (1.11–1.3)
Previous therapy, (%)
50.0 (56.82)
Current therapy, (%)
SOF + DCV
12.0 (13.64)
SOF + DCV + RBV
55.0 (62.50)
SOF + SMV
8.0 (9.09)
SOF + SMV + RBV
13.0 (14.77)
Therapy duration, (%)
12 weeks
75.0 (85.23)
24 weeks
13.0 (14.77)
Therapy outcome, (%)
SVR
87.0 (98.86)
Relapse
1.0 (1.14)
Data are expressed as mean (±SD) or n (%). ALT: alanine aminotransferase; AST: aspartate aminotransferase; DCV: daclatasvir; GGT: gamma-glutamyl transferase; HCV: hepatitis C virus; IQR: interquartile range; RBV: ribavirin; SD: standard deviation; SOF: sofosbuvir; SMV: simeprevir.
